↓ Skip to main content

Cochrane Database of Systematic Reviews

Haloperidol versus placebo for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, November 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
5 X users
facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
291 Mendeley
Title
Haloperidol versus placebo for schizophrenia
Published in
Cochrane database of systematic reviews, November 2013
DOI 10.1002/14651858.cd003082.pub3
Pubmed ID
Authors

Clive E Adams, Hanna Bergman, Claire B Irving, Stephen Lawrie

Abstract

Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 291 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
United Kingdom 1 <1%
India 1 <1%
Portugal 1 <1%
Unknown 286 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 49 17%
Student > Bachelor 34 12%
Researcher 32 11%
Student > Ph. D. Student 30 10%
Other 17 6%
Other 57 20%
Unknown 72 25%
Readers by discipline Count As %
Medicine and Dentistry 90 31%
Psychology 40 14%
Nursing and Health Professions 21 7%
Pharmacology, Toxicology and Pharmaceutical Science 12 4%
Neuroscience 8 3%
Other 39 13%
Unknown 81 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2020.
All research outputs
#1,700,054
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#3,648
of 13,156 outputs
Outputs of similar age
#15,187
of 224,033 outputs
Outputs of similar age from Cochrane database of systematic reviews
#78
of 250 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,033 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 250 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.